Rosas-Sánchez Gilberto Uriel, Germán-Ponciano León Jesús, Puga-Olguín Abraham, Soto Mario Eduardo Flores, Medina Angélica Yanet Nápoles, Muñoz-Carillo José Luis, Rodríguez-Landa Juan Francisco, Soria-Fregozo César
Programa de Estancias Posdoctorales por México, Secretaría de Ciencia, Humanidades, Tecnología e Innovación SECIHTI, Centro Universitario de Los Lagos, Universidad de Guadalajara, Lagos de Moreno 47460, Jalisco, Mexico.
Centro Universitario de Los Lagos, Universidad de Guadalajara, Lagos de Moreno 47460, Jalisco, Mexico.
Biomedicines. 2025 Jul 26;13(8):1831. doi: 10.3390/biomedicines13081831.
The gut microbiota and its interaction with the nervous system through the gut-brain axis (MGB) have been the subject of growing interest in biomedical research. It has been proposed that modulation of microbiota using probiotics could offer a promising therapeutic alternative for mood regulation and the treatment of anxiety and depression disorders. The findings indicate that several probiotic strains, such as and , have demonstrated anxiolytic and antidepressant effects in pre and clinical studies. These effects seem to be mediated by the regulation of the hypothalamic-pituitary-adrenal axis (HPA), the synthesis of neurotransmitters such as serotonin (5-HT) and Gamma-amino-butyric acid (GABA), as well as the modulation of systemic inflammation. However, the lack of standardization in dosing and strain selection, in addition to the scarcity of large-scale clinical studies, limit the applicability of these findings in clinical therapy. Additional research is required to establish standardized therapeutic protocols and better understand the role of probiotics in mental health. The aim of this narrative review is to discuss the relationship between the gut microbiota and the MGB axis in the context of anxiety and depression disorders, the underlying neurobiological mechanisms, as well as the preclinical evidence for the effect of probiotics in modulating these disorders. In this way, an exhaustive search was carried out in scientific databases including PubMed, ScienceDirect, Scopus, and Web of Science. Preclinical research evaluating the effects of different probiotic strains in animal models during chronic treatment was selected, excluding those studies that did not provide access to the full text.
肠道微生物群及其通过肠-脑轴（MGB）与神经系统的相互作用一直是生物医学研究中越来越受关注的主题。有人提出，使用益生菌调节微生物群可为情绪调节以及焦虑和抑郁障碍的治疗提供一种有前景的治疗选择。研究结果表明，几种益生菌菌株，如[具体菌株1]和[具体菌株2]，在临床前和临床研究中已显示出抗焦虑和抗抑郁作用。这些作用似乎是通过调节下丘脑-垂体-肾上腺轴（HPA）、血清素（5-HT）和γ-氨基丁酸（GABA）等神经递质的合成以及全身炎症的调节来介导的。然而，给药和菌株选择缺乏标准化，以及大规模临床研究的稀缺，限制了这些研究结果在临床治疗中的适用性。需要进一步的研究来建立标准化的治疗方案，并更好地了解益生菌在心理健康中的作用。本叙述性综述的目的是讨论在焦虑和抑郁障碍的背景下肠道微生物群与MGB轴之间的关系、潜在的神经生物学机制，以及益生菌调节这些障碍作用的临床前证据。通过这种方式，在包括PubMed、ScienceDirect、Scopus和Web of Science在内的科学数据库中进行了详尽的搜索。选择了评估不同益生菌菌株在慢性治疗期间对动物模型影响的临床前研究，排除了那些无法获取全文的研究。
